Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2019 Mar;11(Suppl 3):S331-S333.
doi: 10.21037/jtd.2018.12.127.

Lymph node metastasis matters

Haruhiko Sugimura  1 , Katsuhiro Yoshimura  1
Affiliations
Editorial

Lymph node metastasis matters

Haruhiko Sugimura et al. J Thorac Dis. 2019 Mar.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: The authors have no conflicts of interest to declare.

Figures

Figure 1
Figure 1
Tumor infiltrating lymphocytes in metastatic squamous cell carcinoma in the lymph nodes. PD1 expression in lymphocytes is shown. Used antibody is anti PD-1, Clone EH33 (CST Japan, Osaka), with 1:50 dilution and colorized by DAB. 20× objective lens (Keyence BZ-9000).
See this image and copyright information in PMC

Comment on

References

    1. Ferrara R, Mezquita L, Texier M, et al. Hyperprogressive Disease in Patients With Advanced Non-Small Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or With Single-Agent Chemotherapy. JAMA Oncol 2018;4:1543-52. 10.1001/jamaoncol.2018.3676 - DOI - PMC - PubMed
    1. Ferrara R, Pilotto S, Caccese M, et al. Do immune checkpoint inhibitors need new studies methodology? J Thorac Dis 2018;10:S1564-S1580. 10.21037/jtd.2018.01.131 - DOI - PMC - PubMed
    1. Seymour L, Bogaerts J, Perrone A, et al. iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. Lancet Oncol 2017;18:e143-e152. 10.1016/S1470-2045(17)30074-8 - DOI - PMC - PubMed
    1. Champiat S, Dercle L, Ammari S, et al. Hyperprogressive Disease Is a New Pattern of Progression in Cancer Patients Treated by Anti-PD-1/PD-L1. Clin Cancer Res 2017;23:1920-8. 10.1158/1078-0432.CCR-16-1741 - DOI - PubMed
    1. Kato S, Goodman A, Walavalkar V, et al. Hyperprogressors after Immunotherapy: Analysis of Genomic Alterations Associated with Accelerated Growth Rate. Clin Cancer Res 2017;23:4242-50. 10.1158/1078-0432.CCR-16-3133 - DOI - PMC - PubMed